Treatment of Pneumocystis carinii pneumonitis with trimethoprim sulfamethoxazole

W. T. Hughes, S. Feldman, S. K. Sanyal

Research output: Contribution to journalArticlepeer-review

Abstract

Pneumocystis carinii pneumonitis (PCP) is fatal in 90 to 100% of cases if no treatment is given. Trimethoprim sulfamethoxazole (TMP SMX) was used at one of two dosage levels in the treatment of 20 children with PCP and cancer. Of 14 patients treated with 20 mg TMP 100 mg SMX/kg/d, 12 recovered and 2 died. Treatment of the fatal cases and one of the patients who recovered was supplemented with pentamidine. When six patients were treated with 4 to 7 mg TMP 20 to 35 mg SMX/kg/d, four recovered and two died. Both fatal cases and one of the patients who recovered were also treated with pentamidine. There were no significant adverse effects from TMP SMX.

Original languageEnglish (US)
Pages (from-to)47-50
Number of pages4
JournalCanadian Medical Association Journal
Volume112
Issue number13
StatePublished - Dec 1 1975

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Treatment of Pneumocystis carinii pneumonitis with trimethoprim sulfamethoxazole'. Together they form a unique fingerprint.

Cite this